2023
Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial
Jamil Y, Park D, Verde L, Sherwood M, Tehrani B, Batchelor W, Frampton J, Damluji A, Nanna M. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial. The American Journal Of Cardiology 2023, 214: 66-76. PMID: 38160927, PMCID: PMC10923116, DOI: 10.1016/j.amjcard.2023.12.045.Peer-Reviewed Original ResearchStable ischemic heart diseaseAnti-anginal agentIntensive medical therapyIschemic heart diseaseMedical therapyQOL metricsHeart diseaseFindings merit further researchMajor adverse cardiovascular eventsAnti-anginal treatmentBARI 2D trialGreater QoL improvementAdverse cardiovascular eventsMyocardial jeopardy indexCardiovascular eventsCause mortalityCardiovascular endpointsClinical confoundersPatient characteristicsDiabetes mellitusHeart failureTherapy intensityClinical outcomesQOL improvementMyocardial infarctionComparison of intravascular ultrasound, optical coherence tomography, and conventional angiography‐guided percutaneous coronary interventions: A systematic review, network meta‐analysis, and meta‐regression
Park D, An S, Jolly N, Attanasio S, Yadav N, Gutierrez J, Nanna M, Rao S, Vij A. Comparison of intravascular ultrasound, optical coherence tomography, and conventional angiography‐guided percutaneous coronary interventions: A systematic review, network meta‐analysis, and meta‐regression. Catheterization And Cardiovascular Interventions 2023, 102: 440-450. PMID: 37483068, PMCID: PMC10908343, DOI: 10.1002/ccd.30784.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPercutaneous coronary interventionOptical coherence tomographyCoronary angiographyIntravascular ultrasoundCoronary interventionCardiac deathClinical outcomesClinical efficacyConventional angiography-guided PCIAngiography-guided percutaneous coronary interventionCoherence tomographyUse of IVUSSuperiority of OCTAdverse cardiovascular eventsRandomized clinical trialsConventional coronary angiographyImaging modalitiesComparative clinical efficacyBest imaging modalityIntracoronary imaging modalityLesion revascularizationPCI guidanceCardiovascular eventsCause mortalityHierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease
Damluji A, Ijaz N, Chung S, Xue Q, Hasan R, Batchelor W, Orkaby A, Kochar A, Nanna M, Roth D, Walston J, Resar J, Gerstenblith G. Hierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease. JACC Advances 2023, 2: 100318. PMID: 37538136, PMCID: PMC10399211, DOI: 10.1016/j.jacadv.2023.100318.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAdverse cardiovascular eventsCognitive impairmentCardiovascular eventsCardiovascular outcomesCardiovascular riskCardiovascular diseaseIncident major adverse cardiovascular eventsOlder adultsAdverse cardiovascular outcomesIncident cardiovascular diseasePhysical frailty phenotypeCoronary artery diseaseMultiple chronic conditionsPoor health outcomesAging Trends StudyFrailty phenotypeArtery diseasePrimary outcomeGeriatric conditionsChronic conditionsNational HealthPhysical frailtyStudy populationHigh risk
2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPrevention
2020
Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults
Zeitouni M, Nanna MG, Sun JL, Chiswell K, Peterson ED, Navar AM. Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. Journal Of The American College Of Cardiology 2020, 76: 653-664. PMID: 32762899, PMCID: PMC7444655, DOI: 10.1016/j.jacc.2020.06.030.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyYears of agePremature myocardial infarctionIntensive lipid-lowering therapyHigh-risk criteriaMyocardial infarctionYoung adultsYounger patientsHigh low-density lipoprotein cholesterolAHA/ACC guidelinesMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolDuke University Medical CenterACC/AHAAdverse cardiovascular eventsRecurrent myocardial infarctionMost young patientsReductase inhibitor therapyFirst myocardial infarctionAmerican Heart AssociationUniversity Medical CenterOlder age groupsCause deathCholesterol guidelinesStatin candidates
2019
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2019, 96: e102-e109. PMID: 31713326, PMCID: PMC7211549, DOI: 10.1002/ccd.28535.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAtrial FibrillationCoronary ThrombosisDual Anti-Platelet TherapyFemaleFibrinolytic AgentsHemorrhageHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeDouble therapyOral anticoagulationAtrial fibrillationTriple therapyAntithrombotic therapyCoronary syndromeCoronary interventionStent thrombosisMajor adverse cardiovascular eventsTriple antithrombotic therapyAdverse cardiovascular eventsDual antiplatelet therapyOptimal antithrombotic therapyGood safety profileRandom-effects modelIschemic outcomesAntiplatelet therapyCardiovascular eventsP2Y12 inhibitorsMedical managementRandomized trialsIntracranial hemorrhageSafety profile